JAK Inhibitors: Key Clinical Facts
Introduction to JAK Inhibitors
- The American College of Rheumatology recommends JAK inhibitors as oral targeted synthetic DMARDs approved for multiple immune-mediated inflammatory diseases, with specific agents having distinct selectivity profiles and approved indications 1, 2
Available Agents and Approved Indications
- JAK inhibitors, including tofacitinib, baricitinib, upadacitinib, ruxolitinib, and filgotinib, have various approved indications such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis 1, 2, 3
Critical Safety Warnings and Boxed Warnings
- The FDA recommends that all JAK inhibitors carry boxed warnings for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis based on data from the tofacitinib ORAL Surveillance trial in RA patients ≥50 years with cardiovascular risk factors 1, 2
- The European Medicines Agency recommends that tofacitinib be used with caution in patients ≥65 years with cardiovascular risk factors due to increased risk of serious infections 1, 2
Absolute Contraindications
- The American College of Rheumatology states that JAK inhibitors are contraindicated in patients with severe active infections, current malignancies, severe hepatic disease, severe renal disease, pregnancy, and lactation 1, 2, 6
Pre-Treatment Screening Requirements
- The European League Against Rheumatism recommends that patients undergo mandatory screening before initiating JAK inhibitor therapy, including patient history, physical examination, laboratory testing, infectious disease screening, vaccination status assessment, and VTE risk factor assessment 6, 3
Monitoring During Treatment
- The American College of Rheumatology recommends regular monitoring of patients on JAK inhibitor therapy, including complete blood count, liver transaminases, lipid levels, and clinical monitoring for infections and thrombotic events 6, 7
Dose Adjustments for Organ Dysfunction
- The FDA recommends dose adjustments for JAK inhibitors in patients with renal impairment, including reducing tofacitinib to 5 mg once daily in patients with CrCl <30 mL/min, and using baricitinib with caution in patients with CrCl 30-60 mL/min 1, 2, 3
Drug Interactions
- The European Medicines Agency warns of important drug interactions requiring dose adjustments, including rifampicin, ketoconazole, and probenecid, which can affect the metabolism of JAK inhibitors 8, 9
Positioning in Treatment Algorithms
- The American College of Rheumatology recommends JAK inhibitors for patients with immune-mediated inflammatory diseases who have failed prior conventional and/or biological therapies, and as monotherapy when methotrexate is contraindicated or not tolerated 6, 4
Special Populations
- The European League Against Rheumatism recommends consideration of dose adjustments in elderly patients (>70 years) and advises against the use of JAK inhibitors in pregnancy and lactation due to potential teratogenic effects and reduced spermatogenesis 1, 2, 9
Comparative Efficacy
- The American College of Rheumatology states that there is currently no direct evidence of superiority regarding efficacy or safety of one JAK inhibitor over another, and that all three JAK inhibitors share similar safety concerns despite different selectivity profiles 6, 4